All publications

Export 167 results:
Author Title Type [ Year(Asc)]
2013
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Dunn DT, Delpech V, Leigh Brown A, UK Collaborative Group on HIV Drug Resistance.  2013.  Dynamics of Non-B HIV Transmission in the UK. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.
Dolling D, Dunn DT, Geretti AM, Sabin CA.  2013.  HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Clin Infect Dis. 56:162-3.
Mackie N, Dunn DT, Dolling D, Garvey L, Harrison LJ, Fearnhill E, Tilston P, Sabin CA, Geretti AM.  2013.  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.
Dolling D, Dunn DT, Sutherland K.A, Pillay D, Mbisa JL, Parry C.M, Post FA, Sabin CA, Cane P A.  2013.  Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 68:2339-43.
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Dunn DT, Delpech V, Leigh Brown A.  2013.  Non-B HIV transmission networks in the UK. 20th International HIV Dynamics & Evolution Conference, 8-11 May 2013.
Castro H, Pillay D, Cane P A, Asboe D, Cambiano V, Phillips AN, Dunn DT.  2013.  Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.
Dolling D, Nelson M, Schwenk A, Churchill D, Pillay D, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2013.  Rapid Increase in the Frequency of Wild Type HIV-1 Drug Resistance Reports among ART-experienced Patients: UK. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.
Waters L., Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn DT, Phillips AN.  2013.  Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 18:213-9.
Koning FA, Castro H, Dunn DT, Tilston P, Cane P A, Mbisa JL.  2013.  Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 68:1220-36.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2013.  Viral Genotype in Subtype C Significantly Influences Plasma Viral Load. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, O’Shea S, Tong W, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2013.  Viral genotype in subtype C significantly influences plasma viral load. 20th International HIV Dynamics & Evolution Conference, 8-11 May 2013.
2012
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Dunn DT, Delpech V, Leigh Brown A.  2012.  Automated Analysis of A1 cluster dynamics in the UK 2007-2010. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.
Castro H, Pillay D, Sabin CA, Dunn DT.  2012.  Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC Med Res Methodol. 12:30.
Bulteel N, Nelson M, Churchill D, Sabin CA.  2012.  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine within the UK CHIC cohort. 18th Annual Conference of the British HIV Association, 18-20 April 2012.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2012.  Estimating the heritability of viral determination of progression rate. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.
Dolling D, Phillips AN, Delpech V, Pillay D, Cane P A, Crook A.M, Shepherd J., Fearnhill E, Hill T, Dunn DT.  2012.  Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med. 13:309-14.
Barber TJ, Harrison LJ, Asboe D, Williams I, Kirk S., Gilson R, Bansi L, Pillay D, Dunn DT.  2012.  Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.
Dolling D, Sabin CA, Delpech V, Smit E, Pozniak A, Williams I, Geretti AM, Mackie N, Pillay D, Dunn DT et al..  2012.  Has a Limit to the Decline in Transmitted Drug Resistance Been Reached? Evidence from a Large Surveillance Study of UK-acquired Infections 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.
Bradshaw D, Dolling D, Booth C, Nelson M, Dunn DT, Asboe D.  2012.  How common is the mutation E138K in the UK? 18th Annual Conference of the British HIV Association, 18-20 April 2012.
Castro H, Dunn DT, Cane P A, Asboe D, Cambiano V, Phillips AN, Pillay D, UK HIV Drug Resistance Database.  2012.  Persistence of transmitted HIV drug resistance mutations. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A167.